Growth HormoneModerate Evidence

Ipamorelin

Also known as: NNC 26-0161

Selective ghrelin mimetic that triggers rapid growth hormone release without affecting cortisol or prolactin.

Benefits

6

Conditions

5

Evidence

Clinical trials, safety studies in adults+ studies

Source

Synthetic ghrelin mimetic pentapeptide

Overview

Selective ghrelin mimetic that triggers rapid growth hormone release without affecting cortisol or prolactin.

Mechanism of Action

Binds ghrelin receptor (GHS-R1a) on pituitary cells, triggers rapid GH release without hypothalamic involvement, no cortisol or prolactin elevation, synergizes with CJC-1295 for optimal pulsatile GH patterns.

Key Benefits

  • Rapid GH pulse induction
  • No cortisol or prolactin spike
  • Improved body composition
  • Enhanced recovery
  • Better sleep
  • Synergistic with GHRH analogs

Clinical Applications

Growth hormone deficiencyAge-related GH declineAthletic recoveryBody composition goalsSleep quality improvement

Dosing Guidelines

Subcutaneous injection

Typical Dose200-300 mcg
Frequency1-3 times daily (often before bed)
Duration8-12 weeks

* Dosing should be individualized. Always consult with a qualified healthcare practitioner.

Research & Evidence

Evidence Level
Moderate
Studies

Clinical trials, safety studies in adults

Summary

Clinical evidence for selective GH release. Good safety profile with minimal side effects. Often combined with CJC-1295 for synergy.

Safety Information

Potential Side Effects

  • Minimal
  • Increased hunger
  • Water retention (mild)
  • Headache

Contraindications

  • Active cancer
  • Pregnancy
  • Breastfeeding

Interactions

  • Synergistic with GHRH analogs

Quick Facts

CategoryGrowth Hormone
SourceSynthetic ghrelin mimetic pentapeptide
Legal StatusResearch compound, not FDA approved
Gabriel Brain Score
79/ 100

Source Your Protocol

Our preferred peptide partner offers lab-tested, COA-verified peptides with optional physician oversight. Sourced from US-regulated facilities.